Eli Lilly’s metastatic breast cancer drug, Verzenio (abemaciclib), has been approved in Australia and Canada, making it the second medicine to be reviewed under an international work-sharing program for new chemical entities (NCEs) that was set up last year.
Australia's Therapeutic Goods Administration and Health Canada carried out a joint review of Verzenio under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium. The...






